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http://dx.doi.org/10.1016/j.ccell.2015.02.005SUMMARYWe conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhi-
bition in ALK-dependent lung cancer cells. We identify members of known resistance pathways and addi-
tional putative resistance drivers. Among the latter were members of the P2Y purinergic receptor family of
G-protein-coupled receptors (P2Y1, P2Y2, and P2Y6). P2Y receptors mediated resistance in part through
a protein-kinase-C (PKC)-dependent mechanism. Moreover, PKC activation alone was sufficient to confer
resistance to ALK inhibitors, whereas combined ALK and PKC inhibition restored sensitivity. We observed
enrichment of gene signatures associated with several resistance drivers (including P2Y receptors) in crizo-
tinib-resistant ALK-rearranged lung tumors compared to treatment-naive controls, supporting a role for
these identified mechanisms in clinical ALK inhibitor resistance.INTRODUCTION
An understanding of the mechanisms by which tumors harbor
primary drug resistance or acquire resistance to targeted thera-
pies is critical for predicting which patients will respond to a
specific therapy and for the identification of additional targetable
pathways to maximize clinical benefit (Garraway and Ja¨nne,
2012). The EML4-ALK fusion protein is an oncogenic driver in a
subset of non-small cell lung cancer (NSCLC) (Soda et al.,
2007). A chromosomal inversion gives rise to EML4-ALK, leading
to ectopic expression of constitutively active ALK tyrosine ki-
nase. Aberrant ALK activity, in turn, upregulates effectors of
cell survival and proliferation, including the MEK/ERK and PI3K
pathways (Shaw et al., 2013).
Crizotinib is an oral MET/anaplastic lymphoma kinase (ALK) in-
hibitor used as first-line therapy in the treatment of advancedSignificance
ALK inhibitors, including crizotinib and ceritinib, have transform
fortunately, responses to these agents are not durable, mot
inform future combinatorial treatment strategies. We assayed
ALK inhibitionwhen overexpressed in ALK-dependent lung can
additional resistance drivers, including several P2Y purinergic
tively, our findings identify a spectrumofmechanisms sufficien
a role for P2Y receptors and PKC signaling in resistance to thNSCLC harboring ALK rearrangements. In addition, newer sec-
ond-generation ALK inhibitors with increased potency and
selectivity against ALK are entering clinical use. Like crizotinib,
these agents are ATP-competitive inhibitors of the ALK tyrosine
kinase, although they are structurally distinct from crizotinib.
Ceritinib (also known as LDK378) is a second-generation inhibi-
tor that has shown remarkable activity in patients with ALK-pos-
itive lung cancer, including individuals with acquired resistance
to crizotinib (Shaw et al., 2013, 2014; Solomon et al., 2014). Cer-
itinib recently received U.S. Food and Drug Administration
approval for use in patients with advanced ALK-rearranged
NSCLC previously treated with crizotinib. However, responses
to ALK inhibitors are short lived, with resistance commonly
occurring within a year.
Since the introduction of crizotinib in the treatment of ALK-
driven NSCLC, gene amplification or secondary mutations ined the treatment of advanced ALK-rearranged NSCLC. Un-
ivating efforts to characterize resistance mechanisms that
over 12,000 genes for the capacity to drive resistance to
cer cells. Alongwith known resistance pathways, we identify
receptors acting in part via protein kinase C (PKC). Collec-
t to confer resistance to ALK inhibitors in NSCLC and suggest
ese agents.
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EML4-ALK have been identified in approximately one-third of tu-
mors with acquired resistance to crizotinib (Choi et al., 2010;
Doebele et al., 2012; Katayama et al., 2012; Sasaki et al.,
2011). Secondary mutations have been shown in vitro to drive
resistance to crizotinib, but not all confer resistance to the struc-
turally distinct second-generation ALK inhibitors (Katayama
et al., 2011, 2012). In addition, activation of epidermal growth
factor receptor (EGFR), KIT, and insulin-like growth factor 1 re-
ceptor (IGF-1R) have been separately identified in a subset of tu-
mors with resistance to crizotinib (Katayama et al., 2012; Lovly
et al., 2014; Sasaki et al., 2011). Resistance to second-genera-
tion ALK inhibitors is less characterized because of the recent
introduction of these agents to the clinic, although secondary
mutations in EML4-ALK have been identified in a subset of tu-
mors with acquired ceritinib resistance (Friboulet et al., 2014).
Notably, no mechanism of resistance to crizotinib or ceritinib
has been identified in up to half of all tumors reported to date
(Doebele et al., 2012; Friboulet et al., 2014; Katayama et al.,
2012). This observation motivates a broad search for additional
resistance mediators that may provide opportunities for novel
therapeutic approaches. We performed a large-scale functional
genetic study to identify genes whose overexpression is suffi-
cient to confer resistance to ALK inhibition.
RESULTS
A Large-Scale Functional Study to Identify Candidate
Drivers of Resistance to ALK Inhibition
We aimed to identify gain-of-function mediators of resistance to
ALK inhibition by systematic perturbation of gene expression.
The Center for Cancer Systems Biology (CCSB)-Broad Lentiviral
Expression Library is a publicly available large-scale open re-
ading frame (ORF) library consisting of 15,885ORFs representing
12,800 human genes (Yang et al., 2011). To identify transcripts
whose overexpression is sufficient to drive resistance to ALK
inhibition, we individually introduced each ORF into an ALK-
dependent lung adenocarcinoma cell line (H3122) with marked
sensitivity to ALK inhibitors. ORF-expressing cells were assayed
for sensitivity both to crizotinib and to the second-generation
ALK inhibitor, TAE684 (Figure 1A). A mutant form (L1152R) of
EML4-ALK known to confer resistance to both crizotinib and sec-
ond-generation ALK inhibitors was used as a positive control
(Figure 1B) (Sasaki et al., 2011). See Experimental Procedures
for a full description of the experimental design.
Statistical analysis of correlation among screening replicates
and estimation of lentiviral infection efficiency were performed
as quality-control measures (Figure S1). 95% of assayed ORFs
met quality-control thresholds and were evaluated for effects
on sensitivity to ALK inhibition (see Experimental Procedures).
Most ORF-expressing cells remained sensitive to crizotinib and
TAE684 (Figure 1C). For H3122 cells expressing each individual
ORF in the library, the differential proliferation in drug was ex-
pressed as the ratio of cell viability in the presence of drug
divided by cell viability in the absence of drug. Differential prolif-
eration for each ORF in crizotinib and TAE684 was then ex-
pressed as a Z score (% viability Z score) to normalize across
the entire data set acquired during the screen (see Experimental
Procedures). ORFs conferring a differential proliferation in
the presence of crizotinib or TAE684 R3 SDs above the mean398 Cancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc.(% viability Z score R3) were selected as candidate mediators
of resistance to ALK inhibition. A total of 75 ORFs representing
67 genes met this criterion, with 43 ORFs yielding a % viability
Z scoreR3 for both drugs (Figure 1D; Figure 2A).
Validation and Characterization of Candidate Drivers of
Resistance to ALK Inhibition in H3122
Next, we performed a validation study in which the 75 candidate
ORFs were subjected to 7-point growth inhibition assays in
H3122 with crizotinib and TAE684. The area under the curve
(AUC) was determined for each ORF. ORFs associated with an
AUCR2.5 SD above themean for either drug (determined in par-
allel from a cohort of control ORFs) were considered validated
resistance drivers in H3122. Overall, 61 ORFs representing 54
genes met this criterion (81% of candidate resistance ORFs
identified from the initial screening study; Figure 2A).
Validated resistance genes reflect diverse protein classes (Fig-
ure 2B). Prominent among these are transcription factors, serine-
threonine and tyrosine kinases, growth factors, and signal trans-
duction adaptor proteins. Resistance profiles of the 54 validated
resistance genes against crizotinib and TAE684 in H3122 are
shown in Figure 2C. Of note, we confirmed that validated genes
also drive resistance to the second-generation ALK inhibitor cer-
itinib, with results comparable to those with TAE684 (Figure S2).
A subset of the ALK resistance genes overlap with resistance
drivers to MAP kinase pathway inhibition identified in BRAF
mutant melanoma (Johannessen et al., 2010, 2013). Among
these are kinases (such as AXL, MAP3K8 [also known as COT],
and RAF1), adaptor proteins (including CRKL and GAB1), and
transcription factors (such as ETV1, FOS, and YAP1). This finding
is not surprising, given the central role of MEK/ERK signaling
in both contexts. However, there are noteworthy differences
between the data sets. For example, growth factors are more
prevalent in the present study and include five epidermal-
growth-factor (EGF)-related peptides (Figure S2). This is consis-
tent with prior reports suggesting a role for EGF ligands and
EGFR activation in resistance to ALK inhibition (Katayama
et al., 2012; Sasaki et al., 2011; Tanimoto et al., 2014; Tanizaki
et al., 2012; Voena et al., 2013; Yamada et al., 2012).More gener-
ally, these results corroborate reports implicating paracrine and
autocrine mechanisms of resistance to targeted therapies (Har-
binski et al., 2012; Straussman et al., 2012; Wilson et al., 2012).
We compared resistance profiles for crizotinib and TAE684
and identified three ORFs (AXL, MST1R, and hepatocyte growth
factor [HGF]) that validated strongly as drivers of resistance to
TAE684 (% viability Z score >5.5) but not crizotinib (% viability
Z score <1; Figure 2D). This discordance likely reflects the phar-
macologic activity of crizotinib against AXL, MST1R, and MET
(the kinase activated by HGF) (Peters and Adjei, 2012). Similar
findings for HGF-mediated resistance to ALK inhibition have
been reported (Tanimoto et al., 2014; Yamada et al., 2012).
Effects of ResistanceORFs onReactivation ofMEK/ERK
and/or PI3K Pathways in H3122
Next, since oncogenic ALK dysregulation activates the MEK/
ERK and PI3K pathways (which promote cell proliferation and
survival), we determined whether ectopically expressed resis-
tance ORFs might confer resistance by reactivation of ERK
and/or AKT in H3122 in the presence of TAE684. Approximately
Figure 1. A Large-Scale ORF Screen Identifies Candidate Mediators of Resistance to ALK Inhibition
(A) Overview of the experimental approach. H3122 cells were spin-infected with the CCSB-Broad Lentiviral Expression Library. ORF-expressing cells were then
treated with crizotinib, TAE684, DMSO, or blasticidin as indicated. Cell viability was determined after 5 days of drug exposure using Cell Titer-Glo.
(B) Growth curves for H3122 cells ectopically expressing Lac Z, wt EML4-ALK, or L1152R EML4-ALK and exposed to crizotinib or TAE684 at varying con-
centrations for 5 days. Mean and SE of three replicates are shown. Results are representative of three independent experiments.
(C) Cell viability (expressed as raw luminescence values) for all assayed ORFs in the presence or absence of drug.
(D)% viability Z scores in the presence of crizotinib or TAE684 for each experimental ORF.% viability Z scores are defined as the normalized ratio of cell viability in
drug to cell viability in drug vehicle (DMSO). % viability Z scores for replicates of the L1152R EML4-ALK positive control are shown in red. Experimental ORFs
associated with a % viability Z scoreR3 were selected as candidate mediators of resistance.
See also Figure S1.half of the resistance ORFs (including a subset of growth factors,
kinases, and adaptor proteins) produced sustained ERK and/or
AKT activation despite ALK inhibition, underscoring the impor-
tance of these pathways in mediating ALK-driven tumorigenesis
(Figure 3). The remaining resistance ORFs had a minimal effect
on these pathways, raising the possibility of resistance modules
that bypass these effectors.
Assessment of Validated ORFs in Resistance to
Targeted Therapies in Other NSCLC Cell Systems
To identify resistancemechanismsmore broadly operant in ALK-
rearranged lung cancer, we assayed the 54 validated resistance
drivers in MGH006, a second ALK-rearranged NSCLC cell line
(Sequist et al., 2010). Of these, 23 conferred resistance to ALK
inhibition in MGH006, as defined by a differential proliferation
in drugs R2.5 SD above the mean (determined from controlORFs) with a single dose of crizotinib or TAE684 (Experimental
Procedures; Figure 4). MGH006 is reported to have a secondary
dependence on EGFR activation and demonstrates reduced
sensitivity to ALK inhibition compared to H3122 (Figure S3) (Ka-
tayama et al., 2012). This observation, coupled with the finding
that ectopic ORF expression was generally lower in MGH006
compared to H3122 (Figure S3), suggests that the resistance ef-
fects observed in MGH006 could be an underestimate. Alterna-
tively, our findings might indicate that certain molecular contexts
enable some resistance mechanisms over others.
Several ALK resistance drivers identified in H3122 (including
AXL, CRKL, and HGF) have previously been implicated in resis-
tance to EGFR inhibitors in EGFR mutant lung cancer (Cheung
et al., 2011; Engelman et al., 2007; Zhang et al., 2012). In addi-
tion, both the MEK/ERK and PI3K pathways are upregulated
by ALK or EGFR activation in lung cancer. We hypothesizedCancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc. 399
Figure 2. Validation of Candidate ORFs as
Drivers of Resistance to ALK Inhibition in
H3122
(A) Summary of initial screening and validation
studies in H3122. 61 experimental ORFs (repre-
senting 54 genes) with a % viability Z scoreR3 for
either drug were validated in H3122 by assessing
viability of ORF-expressing cells in varying con-
centrations of crizotinib and TAE684.
(B) Classification of the 54 genes validated as
mediators of resistance in H3122. TNF Receptor,
tumor necrosis factor receptor.
(C) Heat map displaying normalized AUC for vali-
dated drivers of resistance to crizotinib (CRZ) and
TAE684 (TAE) in H3122 compared to negative
controls (left). GEFs, guanine nucleotide exchange
factors.
(D) Growth curves from H3122 cells expressing
MST1R, AXL, or HGF in crizotinib, or TAE684.
Mean and SE of four replicates are shown. Growth
curves of H3122 cells expressing negative control
ORFs (BFP and HcRed) and the L1152R EML4-
ALK positive control are shown for comparison.
See also Figure S2.that a subset of identified mediators of resistance to ALK inhibi-
tion in H3122 might also drive resistance to EGFR inhibition in
EGFR mutant lung cancer. To test this, we expressed the ALK
resistance ORFs in three EGFR mutant NSCLC lines (HCC827,
HCC4006, and PC-9) and performed inhibition studies with erlo-
tinib (Figure 4; Figure S3). Most ORFs mediating ALK resistance
in H3122 also conferred resistance to erlotinib in EGFR mutant
lines, with 38 of 54 (70%) validating in at least one such line
(Experimental Procedures). As the activating effects of EGF li-
gands are presumably blunted by EGFR inhibition, no EGF li-
gands identified from the ALK inhibitor screen induced resis-
tance to erlotinib. Together, these results raise the possibility
of shared mechanisms of resistance to ALK and EGFR inhibition
in ALK-rearranged and EGFRmutant lung cancers, respectively.
We evaluated the expression of each resistance ORF in all five
cell lines assayed in the initial screening and subsequent valida-
tion studies (Figure S3). The majority of assayed ORFs are
expressed in all cell systems, although a subset of ORFs demon-
strates differential expression across cell lines.
Neuregulin-1 as a Resistance Driver in ALK-Dependent
Lung Cancer Cell Systems
The ORF that most strongly induced resistance to ALK inhibition
in both H3122 andMGH006 was neuregulin-1 (NRG1), the ligand
that activates HER3. Upon ligand binding, HER3 forms hetero-
dimers with HER2 to activate downstream signaling pathways.
To confirm the ORF screening and validation findings for
NRG1, we treated ALK-dependent cell lines with recombinant
NRG1 peptide and assayed resistance to TAE684 (Figures 5A
and 5B). Recombinant NRG1 peptide drives resistance to
TAE684 in ALK-dependent NSCLC cell lines (H3122, H2228,
and MGH006). NRG1 had no impact on sensitivity to TAE684400 Cancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc.in KELLY cells (an ALK-dependent neuro-
blastoma cell line), suggesting a context-
dependent role for NRG1 in driving resis-tance to ALK inhibition. The effect of NRG1 in ALK-dependent
NSCLC cell lines was abrogated with the combination of
TAE684 and lapatinib, which inhibits the activity of HER2 (the
dimerization partner of HER3; Figures 5C and 5D). Together,
these findings suggest a role for HER2/HER3 activation in resis-
tance to ALK inhibition. Of note, NRG1 has recently been identi-
fied as a putative driver alteration in the somatic gene fusion
CD74-NRG1 in a subset of invasive mucinous lung adenocarci-
noma (Fernandez-Cuesta et al., 2014).
Purinergic P2Y Receptors as Resistance Drivers to ALK
Inhibition in H3122
We also examined less characterized ALK resistance ORFs and
associated pathways. Among these is P2Y2 (encoded by
P2RY2), a member of the P2Y subfamily of P2 purinergic recep-
tors. P2Y receptors are membrane-bound G-protein-coupled
receptors (GPCRs) activated in response to extracellular nucleo-
tides including ATP. They are widely expressed in a variety of tis-
sues, including lung epithelia (Schafer et al., 2003). A role has
been postulated for P2Y receptors in mediating the activating ef-
fects of ATP in the tumor microenvironment on tumor growth (Di
Virgilio, 2012). However, a role for these proteins in drug resis-
tance has not previously been demonstrated. There are multiple
P2Y family members that are further subdivided based on
coupling to Gq, Gs, or Gi (Baroja-Mazo et al., 2013). ORFs en-
coding ten P2Y family members are included in the CCSB-Broad
Lentiviral Expression Library. Strikingly, two additional P2Y fam-
ily members (P2Y1 and P2Y6) scored highly in the initial
screening study (% viability Z score, 2–3) but did not meet our
threshold for initial follow-up (Z scoreR3; Figure S4).
Given this observation suggesting that three P2Y family mem-
bers are capable of impacting sensitivity to ALK inhibition in
Figure 3. A Subset of Validated Resistance
ORFs Reactivate MEK/ERK or PI3K Sig-
naling
Protein lysates were prepared from ORF-ex-
pressing H3122 cells after treatment with 100 nM
TAE684 for 8 hr. Immunoblotting was performed
with antibodies against ERK2, phospho-ERK1/
ERK2, AKT, and phospho-AKT. Fluorescence
signal intensity for protein bands was quantitated.
(A) Ratio of pAKT/AKT immunostaining was
determined for each ORF and normalized to mean
pAKT/AKT determined from 13 negative controls
(left). Fold increase in pAKT/AKT relative to con-
trols is shown, with the red horizontal line repre-
senting mean pAKT/AKT from controls.
(B) As in (A), except with pERK/ERK. GEFs, gua-
nine nucleotide exchange factors.
(C) Venn diagram demonstrating overlap between
ORFs reactivating AKT or ERK. Resistance ORFs
associated with a pAKT/AKT or pERK/ERK ratio
R2.5 SD above the mean (as determined from the
negative controls) were designated as ORFs re-
activating AKT or ERK in the presence of TAE684,
respectively. Of 54 resistance ORFs, 28 (52%) met
this criteria for AKT or ERK; 14 of these 28 ORFs
were associated with reactivation of both AKT and
ERK and are indicated in the shaded box.H3122, we examined these GPCRs in further detail. H3122 cells
expressing these P2Y receptors demonstrated a modest but
reproducible decrease in sensitivity to crizotinib in short-term as-
says (Figure S4). P2Y-mediated resistance wasmore apparent in
colony-formation assays, where we observed increased survival
of cells expressing P2Y receptors in crizotinib or ceritinib
compared to the Lac Z control (most notably for P2Y1 and
P2Y2; Figures 6A and 6B).
Resistance Associated with P2Y Receptors Mediated
through Protein Kinase C
We sought to explore the mechanism by which P2Y receptors
mediate resistance to ALK inhibition. Notably, P2Y1, P2Y2,
and P2Y6 each couple to Gq to activate phospholipase C (Bar-
oja-Mazo et al., 2013). Prior studies suggest that P2Y receptors
activate phospholipase C and protein kinase C (PKC) (Falken-
burger et al., 2013). More specifically, P2Y2 has been shown
to activate PKCd in intestinal cells (Amin et al., 2013). Indeed,
we found that H3122 cells overexpressing P2Y1 or P2Y2
(although not P2Y6) had increased levels of activated PKCd (Fig-
ure 6C). To determine whether PKC activation alone is sufficient
to drive resistance to ALK inhibition, we treated H3122 cells with
ceritinib in the presence of the PKC agonist phorbol 12-myristate
13-acetate (PMA). The ceritinib dose required for 50% maximal
inhibition of cell proliferation (GI50) was increased 10-fold in the
presence of PMA (Figure 6D). PKC activation also conferred
resistance to ceritinib in MGH006 (Figure 6D). PMA had no
impact on basal cell proliferation in the absence of ceritinib (Fig-
ure 6E). Using activated PKCd as a marker for PKC activity, weCancer Cell 27, 397–4also observed increased PKC activation
in populations of H3122 cells cultured to
resistance with ceritinib (in addition to
increased EGFR activation as previouslyreported; Figure 6F; Figure S4; Experimental Procedures) (Ka-
tayama et al., 2012; Sasaki et al., 2011).
Sotrastaurin (AEB071) is a pan-PKC inhibitor in clinical trials
(Buder et al., 2013; Chen et al., 2014). The resistance induced
by PMA in H3122 and MGH006 was reversed by sotrastaurin,
consistent with a PKC-dependent phenotype (Figures 6D and
6G). Furthermore, H3122 cells ectopically expressing P2Y
receptors were sensitive to the combination of crizotinib and
sotrastaurin (Figure 6H). The effect appeared specific for P2Y re-
ceptors, as this combination did not impact resistance conferred
by RAF1 (another resistance driver identified from the study;
Figure 6H).
As PKCd is not included in the CCSB-Broad Lentiviral Ex-
pression Library, we tested whether overexpression of PKCd
(encoded by PRKCD) is sufficient to confer resistance to ALK in-
hibition in H3122. We observed that overexpression of PKCd
alone is not sufficient to induce resistance to TAE684 in our
assay, suggesting that other PKC isoforms activated by PMA
and inhibited by sotrastaurin may be driving the observed resis-
tance (Figure S4). Of note, the initial screening study also identi-
fied another PKC isoform, PKCε (encoded by PRKCE), as suffi-
cient to drive resistance to ALK inhibition in H3122 (Figure 2C).
Enrichment of Gene Signatures Associated with
Resistance Drivers in ALK Inhibitor-Resistant Tumors
Compared to Treatment-Naive Controls
Next, we asked whether identified resistance drivers and associ-
ated pathways might play a role in clinical resistance to ALK in-
hibition. We used RNA sequencing (RNA-seq) to generate gene08, March 9, 2015 ª2015 Elsevier Inc. 401
Figure 4. A Subset of Resistance ORFs Identified in H3122 Also Drive Resistance to Targeted Therapies in Other Lung Cancer Cell Systems
Heat map displaying normalized AUC for validated drivers of resistance to crizotinib (CRZ) and TAE684 (TAE) in H3122 compared to negative controls (left) as in
Figure 2C. Normalized%viability for ORF-expressing cells in the indicated doses of CRZ or TAE (forMGH006) or erlotinib (ERL; for HCC827, HCC4006, and PC-9)
are shown. Relative expression of each ectopic experimental ORF in each cell line is shown in Figure S3. Of note, we were unable to demonstrate ectopic
expression of L1152R EML4-ALK inMGH006 (data not shown), and no effect of this positive control ORFwas, therefore, observed on resistance to ALK inhibition
in MGH006. GEFs, guanine nucleotide exchange factors. See also Figure S3.expression profiles from a cohort of ALK-rearranged lung tumors
with acquired resistance to crizotinib and from treatment-naive
ALK-rearranged controls (Table 1). Specimen DFCI76 harbors
a secondary EML4-ALK mutation associated with crizotinib
resistance (Sasaki et al., 2011); all other tumors lacked second-
ary ALK mutations (and activating EGFR or KRAS mutations),
suggesting alternative resistance mechanisms. We used sin-
gle-sample gene set enrichment analysis (ssGSEA) to query
gene expression signatures for enrichment in resistant tumors
compared to controls (Barbie et al., 2009; Konieczkowski
et al., 2014; Subramanian et al., 2005). A total of 286 oncogenic
gene signatures were evaluated, including 189 from the Molecu-
lar Signatures database (Liberzon et al., 2011). These include
signatures associated with activation of a subset of resistance
drivers/pathways identified from our screen, along with a P2Y
signature we derived from overexpression of P2Y receptors in
H3122 (Experimental Procedures; Figure 7A).
Among the gene signatures enriched in resistant tumors
compared to controls (with a false discovery rate [FDR] %0.2)
were five signatures associated with resistance drivers/path-
ways identified from our functional study. Two of these were in-
dependent EGFR signatures (Creighton et al., 2006; Gatza et al.,
2010, 2014), consistent with prior reports of an association be-
tween EGFR activation and clinical resistance to ALK inhibition
(Figure 7B). We also observed the enrichment of HER2 and
RAF1 signatures in resistant tumors, consistent with our findings
of NRG1 (which activates HER2/HER3) and RAF1 as strong
drivers of resistance to ALK inhibition (Figures 4 and 5)
(Creighton et al., 2006; Gatza et al., 2010, 2014). Finally, the
P2Y signature we identified in H3122 cells overexpressing P2Y
receptors was also enriched in crizotinib-resistant tumors (Fig-
ures 7B and 7C; Figure S5; Tables S1 and S2). These findings
suggest activation of transcriptional states associated with
EGFR, HER2, P2Y, and RAF1 in crizotinib-resistant tumors and
likely reflect underlying biological relationships between these
pathways. Examination of expanded patient cohorts will be
necessary to confirm these findings. Of note, many genes and
pathways identified from our functional studies as resistance
drivers are not represented among gene signatures used for
ssGSEA, limiting a computational assessment of those genes/
pathways in resistant tumors compared to controls.402 Cancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc.Given these results, we asked if transcripts encoding EGFR,
HER2, RAF1, or P2Y receptors were increased in resistant tu-
mors. Among these, expression of both P2RY6 and P2RY2
was significantly increased in crizotinib-resistant tumors com-
pared to treatment-naive controls (ps = 0.021 and 0.033, respec-
tively; Figures 7D and 7E). This observation provides further
support for activation of a P2Y gene signature in resistant
tumors.
Expression signatures associated with PKC activation were
not represented in the reference collection of gene signatures
used for the ssGSEAs described earlier. Therefore, we queried
tumor expression profiles against the compendium of expres-
sion signatures associated with chemical perturbations in the
Connectivity Map (CMap) that included PKC agonists (Experi-
mental Procedures; Table S3). Among the ALK-rearranged tu-
mors were a relapsed post-ceritinib (DFCI133) specimen and a
pre-ceritinib (DFCI107) specimen obtained from a single patient
who previously experienced disease progression on crizotinib
(Table 1). Among >3,200 compounds profiled in CMap, the top
three chemical signatures most similar to DFCI133 (compared
to DFCI107) were PKC agonists (Table S4). Although limited to
a single patient, this preliminary observation is suggestive of
PKC activation in a tumor with acquired resistance to ceritinib,
consistent with our functional data. However, we did not identify
a connection between gene signatures induced by PKC agonists
and the entire cohort of unmatched resistant ALK-rearranged tu-
mors compared to treatment-naive controls.
DISCUSSION
Patients with advanced ALK-rearranged lung cancers are
treated with ALK inhibitors, including crizotinib, and newer sec-
ond-generation inhibitors, such as ceritinib or alectinib (Kwak
et al., 2010; Shaw et al., 2014). As responses to these agents
are generally short lived, an understanding of the mechanisms
leading to drug resistance is essential for the design of therapeu-
tic strategies to improve efficacy. Here, we present findings from
a systematic large-scale functional study of resistance to ALK in-
hibition in ALK-rearranged lung cancer. At least 10 of the 54
ORFs identified as potential drivers of resistance to ALK inhibi-
tion represent pathways and proteins previously implicated in
Figure 5. NRG1 Drives Resistance to ALK Inhibition in ALK-Dependent NSCLC Cell Lines but Not in an ALK-Dependent Neuroblastoma Cell
Line: KELLY
(A) H2228, H3122, and KELLY cells were exposed to increasing concentrations of NRG1 at the indicated doses of TAE684 for 5 days. Cell viability was determined
with Cell Titer-Glo. Mean and SE of three replicates are shown.
(B) H2228, H3122, and KELLY cells were exposed to 200 nM TAE684 in the presence or absence of 50 ng/ml NRG1 for 6 hr. Immunoblotting of cell lysates was
performed with the indicated antibodies.
(C) H3122 and MGH006 cells were exposed to 50 ng/ml NRG1 with or without 1 mM lapatinib in varying concentrations of TAE684 for 5 days. Cell viability was
determined as in (A). Mean and SE of three replicates are shown.
(D) H3122 andMGH006 cells were exposed to combinations of 200 nMTAE684, 50 ng/ml NRG1, and 1 mM lapatinib for 6 hr. Immunoblottingwas performed using
the indicated antibodies.clinical resistance to targeted therapies in lung cancer. These
include the EGFR pathway (represented by five EGF ligands
identified from our study), MET activation (represented by
HGF), SRC-related kinases (represented by FGR, LCK, and
LYN), and the AXL receptor tyrosine kinase (Crystal et al.,
2014; Engelman et al., 2007; Katayama et al., 2012; Zhang
et al., 2012). These findings underscore the capacity of a func-
tional genomic approach using appropriate cell line model sys-
tems to identify clinically relevant resistance mechanisms.
Our results provide a landscape of genes capable of driving
resistance to ALK inhibition and offer multiple insights about
resistance pathways. A subset of these resistance drivers define
putative signal transduction networks from cell membrane to nu-
cleus, including growth factors, receptor tyrosine kinases,
adaptor proteins, serine-threonine kinases, transcription factors,
and DNA/RNA binding proteins. Our findings suggest that
increased expression of individual genes representing multiple
nodes of these signal transduction networks is sufficient to drive
resistance to ALK inhibition in an ALK-dependent lung cancer
cell system. We demonstrate that a subset of these findings is
also relevant in the context of resistance to EGFR inhibitors in
EGFR mutant lung cancer. In particular, a number of growth fac-
tors, kinases, and adaptor proteins identified as ALK resistance
drivers that re-activate MEK/ERK and/or PI3K signaling in H3122
also drive resistance to EGFR inhibition in EGFR mutant lines.
This finding highlights the fundamental role of these pathways
in mediating the oncogenic effects of aberrant EGFR and ALK
signaling.
In total, approximately half of the resistance drivers identified
from our study reactivate MEK/ERK and/or PI3K signaling inH3122. Not all resistance drivers impact these pathways, how-
ever, suggesting alternative bypass mechanisms. Members of
the P2Y family of purinergic receptors and downstream PKC
activation represent previously unrecognized mediators of resis-
tance to ALK inhibition. Overexpression of P2Y receptors did not
impact MEK/ERK or PI3K signaling in our assays (Figures 3A and
3B; Figure 6C). However, there are reports suggesting a role for
P2Y receptors in EGFR transactivation andMAP kinase pathway
activation in other cell systems (Buvinic et al., 2007; Kehasse
et al., 2013; Peterson et al., 2010; Ratchford et al., 2010; Sham
et al., 2013; Tamaishi et al., 2011). The observed enrichment
of gene signatures associated with EGFR, HER2, RAF1, and
P2Y in crizotinib-resistant tumors may hint at shared resis-
tance-associated transcriptional targets downstream of these
pathways.
P2Y receptors mediate resistance, at least in part, through
PKC activation. We demonstrate that PKC activation alone is
sufficient to induce resistance to ALK inhibition and is overcome
with combined ALK and PKC inhibition. A recent study of resis-
tance to the BCR-ABL inhibitor imatinib in chronicmyeloid leuke-
mia revealed that upregulation of PKCh confers resistance
by activation of RAF1 and MEK/ERK signaling (Ma et al., 2014).
Further work will be required to characterize the PKC isoforms
driving PKC-mediated resistance in our study. In addition, larger
tumor cohorts will be necessary to determine the prevalence
of P2Y and/or PKC activation in clinical resistance to ALK
inhibition.
In comparing resistance profiles between crizotinib and
second-generation ALK inhibitors in H3122 cells, we identify
HGF (which activates MET), AXL, and MST1R (also known asCancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc. 403
Figure 6. P2Y Receptors Drive Resistance to ALK Inhibition in H3122 via a PKC-Dependent Mechanism
(A) H3122 expressing Lac Z, P2Y1, P2Y2, or P2Y6 were exposed to DMSO for 14 days or 0.3 mM crizotinib (CRZ) or 15 nM ceritinib (CER) for 21 days followed by
staining with crystal violet. Media was changed with fresh drug addition every 3 days.
(B) Quantitation of crystal violet uptake byORF-expressing cells exposed to crizotinib (CRZ) or ceritinib (CER) normalized to Lac Z.Mean and SE are shown for six
(CRZ) or four (CER) independent experiments of three replicates each.
(C) Lysates from H3122 cells overexpressing Lac Z, P2Y1, or P2Y2 were subjected to fractionation and immunoblotting with the indicated antibodies.
(D) H3122 and MGH006 cells were treated with the indicated compounds (1 mM PMA, 0.3 mM sotrastaurin [SOT], or combination) in varying concentrations of
ceritinib. Cell viability was determined after 5 days. Mean and SE of three replicates are shown. Results are representative of four independent experiments with
ceritinib or TAE684.
(E) Cell viability of H3122 and MGH006 treated with 1 mM PMA (normalized to H3122 or MGH006 treated with DMSO as 100%). Mean and SE of three replicates
are shown. The experiment was performed four times.
(F) Lysates from parental (P) or ceritinib-resistant (R1 and R2) H3122 cells were subjected to fractionation and immunoblotting with the indicated antibodies.
(G) Lysates from H3122 and MGH006 cells treated with 1 mM PMA in the presence or absence of 0.3 mM sotrastaurin (SOT) were fractionated. Immunoblotting
was performed with the indicated antibodies.
(H) As in (A), except ORF-expressing cells were exposed to the indicated compounds for 20 days. Results are representative of three independent experiments.
See also Figure S4.RON) as three potential mechanisms of resistance to a second-
generation ALK inhibitor that do not impact sensitivity to crizoti-
nib. As noted earlier, increased expression of both MET and AXL
has been implicated in clinical resistance to EGFR inhibitors in
EGFR mutant lung cancer (Engelman et al., 2007; Zhang et al.,
2012). As crizotinib has activity against MET, AXL, and MST1R
in addition to ALK, our findings suggest that crizotinib may addi-
tionally target at least three receptor tyrosine kinases that are
potential drivers of resistance to ALK inhibition in H3122. This
observation may have therapeutic implications if first-line treat-
ment of advanced ALK-rearranged NSCLC shifts from crizotinib404 Cancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc.to more selective second-generation inhibitors that lack activity
against AXL, MST1R, and MET. Conversely, recent work has
shown that the second-generation ALK inhibitor ceritinib has ac-
tivity against IGF-1R (in addition to ALK), which is a potential
mechanism of resistance to crizotinib (Lovly et al., 2014). Thus,
both crizotinib and second-generation ALK inhibitors may simul-
taneously target distinct potential resistance drivers in addition
to ALK itself.
Our findings nominate several possible agents (including in-
hibitors of EGFR, HER2/HER3, or PKC) that might, in principle,
be combined with ALK inhibition to overcome or delay a range
Table 1. Clinical Characteristics of Patient-Derived Tumors
Sample Age Gender Biopsy Site Status Response PFS (in Months) ALK Mutation
DFCI76 63 F lymph node R PR 2.8 yes (L1152R)
DFCI89a 46 M lung core R PR 14 no
DFCI96a 46 M pleural fluid R PR 14 no
DFCI107b 41 F liver metastasis R PR 6.4 no
DFCI133b 41 F liver metastasis R (ceritinib) SD 7.4 no
DFCI147 61 M lung core R PR 9.8 no
DFCI152 67 F lung core R PR 33.5 no
DFCI171 58 M pleural fluid R PR 3.4 no
DFCI59 40 M lymph node TN NA NA no
DFCI66 63 F lymph node TN NA NA no
DFCI69 46 F lymph node TN NA NA no
DFCI125 58 M pleural fluid TN NA NA no
DFCI142 47 M pleural fluid TN NA NA no
Tumor samples derived from the same patient are indicated with a subscript a or b. Tumors harboring secondary ALK mutations known to be asso-
ciatedwith crizotinib resistance are indicated under ALKMutation. DFCI133was obtained after development of resistance first to crizotinib followed by
ceritinib.
PFS, progression-free survival; F, female;M,male; R, resistant to crizotinib; PR and SD, partial response and stable disease (respectively) by Response
Evaluation Criteria in Solid Tumors, or RECIST criteria; TN, treatment naive; NA, not applicable.of resistance mechanisms. However, an emerging theme from
this and other comprehensive resistance studies is that activa-
tion of multiple pathways may contribute to the drug resistance
phenotype (Huang et al., 2012; Johannessen et al., 2013). This
poses a significant therapeutic challenge, as it may not be
feasible to target all possible resistance pathways. The potential
for ‘‘resistance heterogeneity’’ in the clinical arena may compli-
cate identification of an optimal treatment strategy for individuals
whose tumors acquire resistance to targeted therapies. Repeat
biopsy at disease progression may provide an opportunity for
characterization of resistant tumors to prioritize combinations
for individual patients, but multiple resistance mechanisms
within the same tumor could limit therapeutic efficacy (Gerlinger
et al., 2012). Detailed molecular characterization of patient-
derived tumors might determine the frequency at which specific
resistance mechanisms occur in patients, potentially enabling
prioritization of select therapeutic combinations for clinical trial
design.
In the future, therapeutic disruption of resistance-associated
transcriptional states may provide an alternative to targeting of
individual upstream signaling pathways, inasmuch as such path-
ways might converge onto shared transcriptional outputs that
drive tumor growth in drug-resistant states. Theoretically, this
might be achieved by incorporation of chromatin-modifying
agents as part of an ALK-directed treatment strategy. Such an
approach that does not rely solely on inhibition of upstream
signaling proteins susceptible to bypass might lead to more du-
rable responses to targeted therapies.EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
H3122 cells were obtained from the National Cancer Institute. Generation of
ceritinib-resistant H3122 cells is described in the Supplemental Experimental
Procedures. H2228, HCC827, and HCC4006 were purchased from the Amer-
ican Type Culture Collection (ATCC). PC-9 cells were obtained from PublicHealth England, and KELLY neuroblastoma cells were obtained from Sigma-
Aldrich. Cells were maintained in RPMI-1640 (Cellgro) with 10% fetal
bovine serum (Gemini Bioproducts) and penicillin (100 U/ml)/streptomycin
(100 mg/ml) (Cellgro). MGH006 cells have been previously reported and were
maintained in DMEM (Cellgro) with 10% fetal bovine serum, penicillin, and
streptomycin (Sequist et al., 2010). All cell lines were tested to confirm the
absence ofmycoplasma contamination. Crizotinib, TAE684, ceritinib, erlotinib,
lapatinib, and sotrastaurin were purchased from Selleck Chemicals. Blastici-
din was obtained from Life Technologies. PMA was purchased from Santa
Cruz Biotechnology.
Screening of the CCSB-Broad Lentiviral Expression Library
The CCSB-Broad Lentiviral Expression library has been previously described
(Yang et al., 2011). Additional information is included in the Supplemental
Experimental Procedures. H3122 cells were seeded in white clear-bottom
384-well microtiter plates at 1,500 cells per well using a Multidrop Combi
(Thermo-Scientific). The next day, cells were spin-infected with the expression
library (or L1152R EML4-ALK as a positive control) in the presence of 4 mg/ml
polybrene at 2,250 rpm for 30 min at 37C. Cells were infected in seven repli-
cates. Virus was removed after 24 hr and replaced with standard growthmedia
(containing 12 mg/ml blasticidin for one replicate). After an additional 48 hr, the
remaining six replicates of ORF-expressing cells were treated with 0.01%
DMSO (drug vehicle), 1 mM crizotinib, or 30 nM TAE684 (two replicates
each). Lentiviral infection, media change, and drug addition were all performed
with robotics. Following 5 days of drug exposure, cell viability was determined
using the Cell Titer-Glo luminescent assay (Promega) according to the manu-
facturer’s instructions. Luminescence was measured with an EnVision Multila-
bel Reader (Perkin-Elmer). Screening of the entire CCSB-Broad Lentiviral
Expression Library (which is arrayed in forty-seven 384-well plates) was per-
formed in seven batches. Identification and validation of candidate resistance
ORFs (and associated statistical analyses) are described in the Supplemental
Experimental Procedures.
Antibodies and Immunoblotting
Cells were lysed in 50 mM HEPES (pH 7.5), 1% Triton X-100, 10% glycerol,
150 mM NaCl, 2 mM EDTA, and 10 mM NaF with protease inhibitors (Roche)
and phosphatase inhibitors (Calbiochem). Lysates were fractionated by
SDS-PAGE and transferred to nitrocellulose membranes using the iBlot
system (Life Technologies). Two-color immunoblotting was performed using
LI-COR reagents (Odyssey Blocking Buffer and IRDye 800CW and IRDye
680RD secondary antibodies) according to the manufacturer’s instructionsCancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc. 405
Figure 7. Enrichment of Gene Expression
Signatures in ALK Inhibitor-Resistant ALK-
Positive Lung Tumors Compared to Treat-
ment-Naive ALK-Positive Lung Tumors
(A) Overview of the experimental approach to
generate a P2Y gene signature in vitro and to then
query this signature (along with 285 additional gene
signatures) for enrichment in ALK inhibitor-resistant
ALK-rearranged lung tumors compared to treat-
ment-naive controls.
(B) Identification of five gene signatures enriched
in resistant tumors compared to treatment-
naive using ssGSEA. Two independent EGFR sig-
natures were identified; EGFR (1) and EGFR (2) are
reported by Creighton et al. (2006) and Gatza et al.
(2010), respectively. Index values range from 1 to
1 and refer to correlation between the indicated
gene set and enrichment in resistant, compared
to treatment-naive, tumors (see Experimental Pro-
cedures). Rank positions according to index
value for gene signatures (out of 286 total signa-
tures) are indicated. The p values were determined
using a permutation test with 1,000 permutations
of the indicated profile (see Experimental Pro-
cedures).
(C) Gene set enrichment analysis reveals that 76 of
the top 200 genes upregulated in the P2Y gene
signature (P2Y_UP) are also upregulated in ALK
inhibitor-resistant tumors compared to treatment-
naive tumors. NES, normalized enrichment score;
FWER p-value, family-wise error rate p value.
(D) Expression of P2RY6 from RNA-seq of treat-
ment-naive (‘‘Pre-treatment’’) and ALK inhibitor-
resistant (’’resistant’’) tumors. Expression is indicated in RPKM. Mean and SE are shown. ALK inhibitor-resistant tumors obtained from the same patient are
indicated in red or blue. The p value was determined using a one-tailed Mann-Whitney nonparametric test.
(E) As in (D), except for P2RY2.
See also Figure S5 and Tables S1, S2, S3, and S4.(LI-COR Biosciences). Fluorescence detection was performed using an Odys-
sey CLx Infrared Imaging System, and quantitation was performed using Im-
age Studio software (LI-COR). Antibodies against ALK (#3791), AKT (#2920),
phospho-AKT (Ser 473; #4060), EGFR (#2239), phospho-EGFR (Tyr 1068;
#3777), PKCd (#9616), and phospho-PKCd (Tyr 311; #2055) were obtained
from Cell Signaling. ERK2 antibody (sc-154) was purchased from Santa Cruz
Biotechnology. Antibodies against phospho-ERK1/ERK2 (Thr 185/Tyr 187;
#M8159) and vinculin (#V9131) were obtained from Sigma. V5 antibody
(#R960-25) was obtained from Life Technologies. In-cell western blotting is
described in the Supplemental Experimental Procedures.
Colony-Formation Assays
H3122 cells were seeded in 12-well plates at a density of 10,000–20,000 cells
per well. The following day, cells were spin-infected with lentivirus harboring
the indicated ORFs in the presence of 4 mg/ml polybrene. Virus was removed
after 24 hr and replaced with standard growth media. After an additional 24–
48 hr, cells were treated with drug or DMSO as indicated. Cells were
exposed to drug or DMSO for 14–21 days, with media change and fresh
drug addition every 3 days. Cells were fixed with 4% formaldehyde and
stained with 0.5% crystal violet. Cells were photographed using a Leica mi-
croscope and imaging software. Quantification of crystal violet uptake for
each sample was determined by de-staining cells with 10% acetic acid
and measurement of absorbance at 595 nm using a SpectraMax 190 instru-
ment (Molecular Devices).
RNA-seq
Patients with ALK-rearranged NSCLCwere identified from the LoweCenter for
Thoracic Oncology at the Dana-Farber Cancer Institute (DFCI). Tumor samples
were obtained under a protocol approved by the DFCI Institutional Review406 Cancer Cell 27, 397–408, March 9, 2015 ª2015 Elsevier Inc.Board (IRB), and all participating patients provided written informed consent.
Total RNA was extracted from fresh frozen tumor specimens using TRIzol (Life
Technologies) according to the manufacturer’s instructions. The presence of
the EML4-ALK fusion transcript was confirmed by RT-PCR for each tumor.
We also prepared total RNA from H3122 cells expressing P2Y receptors for
RNA-seq. Parental H3122 cells or H3122 expressing ectopic Lac Z, P2Y1, or
P2Y2 were exposed to 100 nM TAE684 for 12 hr. (Experimental samples
were H3122 cells expressing P2Y1 or P2Y2; control samples were parental
H3122 and H3122 cells expressing Lac Z.) Total RNA was extracted using
the RNeasy kit (QIAGEN) with on-column DNase treatment.
cDNA libraries were generated for tumor and cell line samples using the Tru-
Seq Sample Preparation Kit (Illumina) with polyA selection according to the
manufacturer’s protocol (Revision A). Libraries were pooled using indexed
adapters for multiplexing. Pooled libraries were normalized to 2 nM and dena-
tured using 0.2 NNaOH prior to sequencing. Flow cell cluster amplification and
sequencing were performed according to the manufacturer’s protocols using
either the HiSeq 2000 or HiSeq 2500 to a depth of 45–50million reads per sam-
ple (paired-end with 76 base-pair reads).
Data were analyzed using the Broad Picard Pipeline, which includes de-mul-
tiplexing and data aggregation. Reads were mapped to the reference human
genome (hg19) using TopHat 1.4.1. Expression levels for each gene were de-
noted as RPKM (reads per kilobase of transcript per million mapped reads)
values determined using Cufflinks 2.0.2. Genes that were not expressed in
any patient-derived tumor samples (RPKM = 0) were removed from the tumor
data set; genes not expressed in the cell line samples were removed from the
cell line data set. Differential transcript expression was determined with the
signal-to-noise test statistic, with an SD at least 20% of the class mean. A
description of the methods used to analyze RNA-seq gene expression data
is provided in the Supplemental Experimental Procedures.
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